Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
Amgen on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.
Amgen also said its experimental cancer drug AMG510 has shown activity in patients with colorectal and appendiceal cancer, helping to boost the company's shares by nearly 3% to $181 in extended trading.
The U.S. biotechnology company, which presented data in June showing that AMG510 also appeared to be effective against lung cancer, said it may begin a trial later this year that could serve as the basis for a U.S. regulatory application seeking approval.
AMG510 is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of in which organ the disease originated.
"I'm very impressed with the emerging safety profile that we are seeing with AMG510," David Reese, Amgen's head of research and development, said on a conference call on Tuesday.
Amgen said second-quarter adjusted earnings per share rose 4% to $3.97, topping analysts' average expectations by 41 cents, according to IBES data from Refinitiv. A lower number of outstanding shares contributed to the earnings beat.
Total revenue of $5.87 billion, while lower than a year ago, topped analysts' estimates of $5.66 billion.
"Amgen had a good quarter all around," said Jefferies analyst Michael Yee. "They tightened up guidance to the higher end of the range, which is where the Street is at."
The company raised the lower end of its full-year outlook and now expects adjusted earnings of $13.75 to $14.30 per share on revenue of $22.4 billion to $22.9 billion. It had previously forecast $13.25 to $14.30 per share on revenue of $22 billion to $22.9 billion.
Sales of potent cholesterol fighter Repatha rose 3% to $152 million, below Wall Street estimates of $157 million. Sales of Amgen's new migraine drug Aimovig, which competes with similar new treatments from Eli Lilly and Teva, totaled $83 million for the quarter, beating the $77.4 million projected by analysts.
But sales of Neulasta, which fights infections by boosting white blood cells, fell 25% to $824 million, while sales of kidney drug Sensipar plunged 71% to $122 million as competition from cheaper generics and biosimilars increased.
Amgen reported a net profit of $2.17 billion, or $3.57 per share, for the quarter, compared with a profit of $2.29 billion, or $3.50 per share, a year ago.